Close

BIO Investor Forum Concludes

Oct 18 2017
The BIO Investor Forum finished today after hosting two days of expert-led panel discussions, fireside chats, over 165 company presentations and more than 2,750 individual meetings arranged through BIO One-on-One Partnering — a 26 percent increase over last year. The event was attended by more than 1,000 representatives of private and early stage biotech companies, leading investment firms, research organizations and others who came together to foster the development of new medical treatments and to grow the industry’s pipeline. 

Hill Leaders Urge Support for Reg System that Supports Ag Innovation

Oct 17 2017
USDA, FDA and EPA must “coordinate with each other and stakeholders”  Washington, D.C. (October 17, 2017) – Under the leadership of Reps. Neal Dunn (R-Fla.) and Jimmy Panetta (D-Calif.), 79 Members of the House of Representatives signed on to a letter urging for a “consistent, science-based, risk-proportionate regulatory system” for agricultural biotechnology.

BIO Statement on California Governor Brown Signing Drug Price Reporting & Transparency Bill

Oct 9 2017
BIO will continue to oppose legislative efforts, such as SB 17, that harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through misguided government intrusion.

BIO Congratulates SAB Biotherapeutics on Pharm Groundbreaking

Oct 5 2017
Sioux Falls, S.D. 80-acre biological pharm is first-of-its kind   Washington, D.C. (October 5, 2017) – Sioux Falls, S.D.-based SAB Biotherapeutics, Inc. (SAB), celebrated construction of their 80-acre biopharmaceutical production pharm operation with a groundbreaking ceremony today in Lincoln County. 

Sixth Annual BIO Patient and Health Advocacy Summit Concludes Today

Oct 3 2017
The 2017 Patient and Health Advocacy Summit wrapped up today, having offered the nearly 240 patient groups, companies and organizations new ways to connect, strategize, learn and partner.  For the past six years, the BIO Patient and Health Advocacy Summit has brought together a diverse group of organizations including patient advocacy, health care providers, academia, government, think tanks, professional societies and the biotechnology industry to focus on bringing the patients’ voice to the drug development process. 

BIO to Offer Complimentary Access to One-on-One Partnering™ During J.P. Morgan Healthcare Conference (“JPM Week”)

Sep 28 2017
BIO will offer complimentary access to its proprietary BIO One-on-One Partnering™ during "JPM" week January 7-11, 2018  

BIO Statement on California’s Drug Price Reporting & Transparency Bill

Sep 13 2017
California Senate Bill 17 is bad for patient and does not deliver on its purported promises

FDA Commissioner, Dr. Scott Gottlieb, to Address BIO Patient and Health Advocacy Summit

Sep 5 2017
The head of the United States Food and Drug Administration, Dr. Scott Gottlieb, will be the keynote speaker at the BIO Patient and Health Advocacy Summit, October 2-3 at the Mayflower Hotel in Washington, DC. The annual event brings together attendees representing patient advocacy groups, health care providers, academia, government, think tanks, professional societies and the biotechnology industry and provides a forum for lively discussions on timely health policy issues and best practices. 

PhRMA and BIO Initiate Litigation to Challenge Unconstitutional Provisions of Nevada’s SB 539

Sep 1 2017
Washington, DC (September 1, 2017) – The Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) today initiated litigation in the United States District Court for the District of Nevada challenging provisions of SB 539, a Nevada law that would violate patent rights and negate trade secret protection for designated diabetes medicines in a way that would harm patients and chill future biomedical innovation.

BIO Asks EPA To Use a Forward-Looking Methodology in Setting Renewable Fuel Standards

Aug 31 2017
BIO today submitted comments on EPA's proposed rule on the Renewable Fuel Standard Program: Standards for 2018 and Biomass-Based Diesel Volume for 2019.